Mr. Rice’s experience, qualifications, attributes and skills include having served as Chief Executive Officer of Andrx Corporation, Fort Lauderdale, Florida (specialty pharmaceuticals) (“Andrx”), from February 2004 to November 2006, when Andrx was sold to Watson Pharmaceuticals. Following the sale, Mr. Rice returned as General Manager and Majority Partner of Columbia Investments LLC, Baltimore, Maryland, which invests in local emerging businesses in Baltimore and which Mr. Rice co-founded in January 1996. He was also a Director of Par Pharmaceuticals, Woodcliff Lake, NJ (drug development, manufacture, and marketing) until November 2012. From January 1999 to March 2003, he was President and Chief Executive Officer of Chesapeake Biological Laboratories, Inc., Solomons, Maryland (pharmaceuticals manufacturing) (“Chesapeake”). Before co-founding Columbia Investments LLC, Mr. Rice served as Executive Vice President and Chief Operating Officer of Circa Pharmaceuticals, Inc., Copiague, New York (pharmaceuticals manufacturing) (“Circa”), from June 1993 to January 1996. Mr. Rice was also the Chief Financial Officer of Circa from June 1993 to January 1995. Prior to joining Circa, Mr. Rice spent seven years as an accountant with Deloitte & Touche LLP, an international accounting firm. He earned a Master’s degree in finance from Loyola University. He was a director of Circa from June 1993 to January 1996, a director of Chesapeake from January 1997 to January 1999 and a director of Andrx from April 2003 to November 2006.
What is Thomas P. Rice's net worth?
The estimated net worth of Thomas P. Rice is at least $2.87 million as of June 17th, 2021. Mr. Rice owns 5,188 shares of Chemed stock worth more than $2,872,959 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Rice may own. Learn More about Thomas P. Rice's net worth.
How do I contact Thomas P. Rice?
Has Thomas P. Rice been buying or selling shares of Chemed?
Thomas P. Rice has not been actively trading shares of Chemed over the course of the past ninety days. Most recently, Thomas P. Rice sold 841 shares of the business's stock in a transaction on Thursday, June 17th. The shares were sold at an average price of $462.47, for a transaction totalling $388,937.27. Following the completion of the sale, the director now directly owns 5,188 shares of the company's stock, valued at $2,399,294.36. Learn More on Thomas P. Rice's trading history.
Who are Chemed's active insiders?
Chemed's insider roster includes Patrick Grace (Director), Brian Judkins (VP), Spencer Lee (EVP), Kevin McNamara (CEO), Thomas Rice (Director), Donald Saunders (Director), George Walsh, III (Director), Nicholas Westfall (EVP), Nicholas Westfall (EVP), David Williams (CFO), and Michael Witzeman (VP). Learn More on Chemed's active insiders.
Are insiders buying or selling shares of Chemed?
During the last twelve months, insiders at the sold shares 15 times. They sold a total of 33,236 shares worth more than $20,128,308.68. The most recent insider tranaction occured on September, 26th when CEO Kevin J Mcnamara sold 2,000 shares worth more than $1,197,620.00. Insiders at Chemed own 3.3% of the company.
Learn More about insider trades at Chemed. Information on this page was last updated on 9/26/2024.